Cardax Inc. (CDXI)
Stock Price:
$3.50 USD
0.00 (0.00%)
Updated Sep 18, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
2.66M |
| Revenue (ttm) |
777,920 |
| Net Income (ttm) |
-5.58M |
| Shares Out |
758,904 |
| EPS (ttm) |
-7.91 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 18, 2020 |
| Last Price |
$3.50 |
| Previous Close |
$3.50 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
3.50 - 3.60 |
| Day's Volume |
0 |
| 52-Week Range |
2.00 - 15.00 |
More Stats
| Market Cap |
2.66M |
| Enterprise Value |
6.55M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
758,904 |
| Float |
575,200 |
| EPS (basic) |
-7.18 |
| EPS (diluted) |
-7.91 |
| FCF / Share |
-3.26 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.92 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.41 |
| PB Ratio |
n/a |
| Revenue |
777,920 |
| Operating Income |
-3.61M |
| Net Income |
-5.58M |
| Free Cash Flow |
-2.46M |
| Net Cash |
-3.90M |
| Net Cash / Share |
-5.14 |
| Gross Margin |
46.99% |
| Operating Margin |
-463.86% |
| Profit Margin |
-717.20% |
| FCF Margin |
-315.90% |
| ROA |
-118.71% |
| ROE |
n/a |
| ROIC |
94.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
200
Current: $3.50
High
200
Target: 200.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 0.71 | 1.51 | 0.61 | 0.04 | - | - | - | 0.01 |
| Revenue Growth | -52.94% | 147.55% | 1631.02% | - | - | - | - | - |
| Gross Profit | 0.37 | 0.81 | 0.34 | 0.02 | - | - | - | 0.01 |
| Operating Income | -4.08 | -4.02 | -2.00 | -1.83 | -4.40 | -16.88 | -3.61 | -1.80 |
| Net Income | -5.09 | -4.02 | -1.99 | -1.78 | -4.26 | -16.99 | -4.36 | -2.54 |
| Shares Outstanding | 0.68 | 0.64 | 0.50 | 0.38 | 0.33 | 0.30 | 0.17 | 0.05 |
| Earnings Per Share | -7.49 | -6.32 | -4.00 | -4.00 | -12.00 | -56.00 | -26.00 | -54.00 |
| Operating Cash Flow | -3.52 | -3.20 | -2.08 | -1.26 | -1.51 | -5.70 | -4.13 | -1.16 |
| Capital Expenditures | - | - | - | - | 0.01 | 0.09 | -0.03 | - |
| Free Cash Flow | -3.52 | -3.20 | -2.08 | -1.26 | -1.50 | -5.61 | -4.16 | -1.16 |
| Cash & Equivalents | 0.02 | 0.24 | 2.24 | 0.16 | 0.32 | 0.04 | 0.22 | 0.01 |
| Total Debt | 2.59 | - | - | - | - | - | 9.04 | 4.11 |
| Net Cash / Debt | -2.57 | 0.24 | 2.24 | 0.16 | 0.32 | 0.04 | -8.82 | -4.10 |
| Assets | 2.02 | 2.46 | 3.16 | 0.75 | 0.85 | 1.55 | 1.77 | 1.48 |
| Liabilities | 9.22 | 5.99 | 4.56 | 4.64 | 4.60 | 4.76 | 14.70 | 10.07 |
| Book Value | -7.20 | -3.54 | -1.41 | -3.89 | -3.75 | -3.21 | -12.94 | -8.58 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cardax Inc. |
| Country |
United States |
| Employees |
11 |
| CEO |
David G. Watumull |
Stock Information
| Ticker Symbol |
CDXI |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: CDXI |
Description
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an anti-inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate; and CDX-301, a zeaxanthin pharmaceutical candidate for pharmaceutical applications. The company has a joint development and supply agreement with BASF SE, as well as a collaboration agreement with Capsugel US, LLC for the development of astaxanthin products for the consumer health market. Cardax, Inc. is based in Honolulu, Hawaii.